Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis Pharmaceutical Investing
Aurinia Pharmaceuticals Inc. Class Action: Levi & Korsinsky Reminds Aurinia Pharmaceuticals Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 14, 2022 - AUPH Pharmaceutical Investing
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Aurinia Pharmaceuticals Inc. Pharmaceutical Investing
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of TASK, MYPS and AUPH Pharmaceutical Investing
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® Market News
DEADLINE ALERT for GWGH, ABBV, MYPS, and SDIG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders Pharmaceutical Investing
LAWSUITS FILED AGAINST AFRM, AKBA and AUPH - Jakubowitz Law Pursues Shareholders Claims Pharmaceutical Investing
EQUITY ALERT: Rosen Law Firm Encourages Aurinia Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AUPH Pharmaceutical Investing
CLASS ACTION UPDATE for AI, SDIG and AUPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders Pharmaceutical Investing
Bronstein, Gewirtz & Grossman, LLC Notifies Aurinia Pharmaceuticals Inc. Investors of Class Action and Encourages Investors to Contact the Firm Pharmaceutical Investing
LAWSUITS FILED AGAINST MP, CRNC and ABBV - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS Pharmaceutical Investing
ROSEN, A TOP RANKED FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABBV Pharmaceutical Investing
